Bailard, Inc. Zentalis Pharmaceuticals, Inc. Transaction History

Bailard, Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$66.92 - $84.79 $1.74 Million - $2.2 Million	-26,000 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$46.83 - $73.5 $257,565 - $404,250	-5,500 Reduced 17.46%	26,000 $1.73 Million
Q2 2021 Aug 13, 2021	BUY	$37.41 - $62.25 $1.18 Million - $1.96 Million	31,500 New	31,500 $1.68 Million

142

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $170M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.